Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EyePoint, Inc.EYPT · Entity 5702 | Director | July 12, 2024 | July 16, 2024 |
| IVERIC bio, Inc.ISEE · Entity 111416 | Director · Executive Chairman | December 18, 2020 | December 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EyePoint, Inc.
Report date July 12, 2024 · Filed July 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,850 |
Ending reported balance
After 2024-07-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-07-12 · Exercise / conversion · Acquired 3,250 · Balance 6,950 Row 2 · 2024-07-12 · Exercise / conversion · Acquired 6,525 · Balance 13,475 Row 3 · 2024-07-12 · Sale · Disposed 11,625 · Balance 1,850 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2033-06-19 | Direct | 3,250 |
Reported balance
After 2024-07-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-07-12 · Exercise / conversion · Disposed 3,250 · Balance 3,250 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.26 · Expires 2033-06-19 | Direct | 6,525 |
Reported balance
After 2024-07-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-07-12 · Exercise / conversion · Disposed 6,525 · Balance 6,525 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
IVERIC bio, Inc.
Report date December 18, 2020 · Filed December 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2030-12-17 | Direct | 205,150 |
Reported balance
After 2020-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-18 · Grant · Acquired 205,150 · Balance 205,150 F1: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 102,630 |
Reported balance
After 2020-12-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-18 · Grant · Acquired 102,630 · Balance 102,630 F2: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant.
F2: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
F3: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 12, 2024 Filed Jul 16, 2024 16:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,525 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-005752 · primarydocument.xml · derivative · entry 5 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,525 Underlying: Common Stock · 6,525 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 16:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001562180-24-005752 · primarydocument.xml · derivative · entry 4 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 3,250 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 16:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 11,625 | $10.06 | $116,995.16 |
DisclosureSEC source: 0001562180-24-005752 · primarydocument.xml · nonDerivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,850 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 16:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 6,525 | $3.26 | $21,271.50 |
DisclosureSEC source: 0001562180-24-005752 · primarydocument.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 16:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 3,250 | $3.50 | $11,375.00 |
DisclosureSEC source: 0001562180-24-005752 · primarydocument.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 16:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,525 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-004638 · primarydocument.xml · derivative · entry 5 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,050 Underlying: Common Stock · 6,525 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 16:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001562180-24-004638 · primarydocument.xml · derivative · entry 4 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 3,250 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 16:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 11,625 | $10.30 | $119,704.95 |
DisclosureSEC source: 0001562180-24-004638 · primarydocument.xml · nonDerivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.87. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 16:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 3,250 | $3.50 | $11,375.00 |
DisclosureSEC source: 0001562180-24-004638 · primarydocument.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 16:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 6,525 | $3.26 | $21,271.50 |
DisclosureSEC source: 0001562180-24-004638 · primarydocument.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,525 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-004106 · primarydocument.xml · derivative · entry 5 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,575 Underlying: Common Stock · 6,525 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001562180-24-004106 · primarydocument.xml · derivative · entry 4 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,750 Underlying: Common Stock · 3,250 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 11,625 | $12.65 | $147,044.63 |
DisclosureSEC source: 0001562180-24-004106 · primarydocument.xml · nonDerivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,550 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.44 to $12.83. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 3,250 | $3.50 | $11,375.00 |
DisclosureSEC source: 0001562180-24-004106 · primarydocument.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 6,525 | $3.26 | $21,271.50 |
DisclosureSEC source: 0001562180-24-004106 · primarydocument.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 20:56 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 25,014 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000396 · primarydocument.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,014 Underlying: Common Stock · 25,014 shares Expires 2034-01-04 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 09:22 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001562180-23-005451 · primarydocument.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2033-06-19 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 09:22 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 26,100 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-23-005451 · primarydocument.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock · 26,100 shares Expires 2033-06-19 Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 17:08 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-001338 · primarydocument.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date. F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 17:08 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-001338 · primarydocument.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:54 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-22-001419 · primarydocument.xml · derivative · entry 4 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 11,000 shares Expires 2032-02-09 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:54 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001419 · primarydocument.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_date: Will fully vest on the one-year anniversary of the grant date. F2 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:54 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001419 · primarydocument.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date. F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:54 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001419 · primarydocument.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:30 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-21-004458 · primarydocument.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-02-09 Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:30 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004458 · primarydocument.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 19:22 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 1,900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001815 · primarydocument.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 19:22 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001815 · primarydocument.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 17:49 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 102,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138669 · tm2039210-1_4.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,630 Underlying: Common Stock · 102,630 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 17:49 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 205,150 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001104659-20-138669 · tm2039210-1_4.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,150 Underlying: Common Stock · 205,150 shares Expires 2030-12-17 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 14:48 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | SaleCommon Stock | 9,270 | $7.16 | $66,373.20 |
DisclosureSEC source: 0001104659-20-135677 · tm2038552-3_4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,113 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on December 12, 2020. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $6.98 to $7.34 on December 14, 2020 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 12, 2020 Filed Dec 15, 2020 14:48 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 17,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-135677 · tm2038552-3_4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Underlying: Common Stock · 17,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On December 12, 2018, the Reporting Person was granted 68,800 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. F4 · derivative.expiration_date: On December 12, 2018, the Reporting Person was granted 68,800 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. Read SEC document |
| December 12, 2020 Filed Dec 15, 2020 14:48 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 17,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-135677 · tm2038552-3_4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 20:59 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | SaleCommon Stock | 9,602 | $6.96 | $66,829.92 |
DisclosureSEC source: 0001104659-20-134929 · tm2038354-1_4seq1.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,183 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on December 9, 2020. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $6.83 to $7.05 on December 10, 2020 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 20:59 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 17,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-134929 · tm2038354-1_4seq1.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,437 Underlying: Common Stock · 17,813 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On December 9, 2019, the Reporting Person was granted an award of 71,250 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. F4 · derivative.expiration_date: On December 9, 2019, the Reporting Person was granted an award of 71,250 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 20:59 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 17,813 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-134929 · tm2038354-1_4seq1.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:25 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002051 · primarydocument.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:25 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002051 · primarydocument.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 19:31 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | SaleCommon Stock | 3,367 | $8.07 | $27,171.69 |
DisclosureSEC source: 0001104659-20-002077 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,972 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on January 4, 2020. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 19:31 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-002077 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F3 · derivative.exercise_date: On January 4, 2016, the Reporting Person was granted an award of 25,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. F3 · derivative.expiration_date: On January 4, 2016, the Reporting Person was granted an award of 25,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 19:31 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-002077 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 17:25 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | SaleCommon Stock | 9,275 | $6.60 | $61,215.00 |
DisclosureSEC source: 0001104659-19-073113 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,089 Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 17:25 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 17,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-073113 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,600 Underlying: Common Stock · 17,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: On December 12, 2018, the Reporting Person was granted 68,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. F2 · derivative.expiration_date: On December 12, 2018, the Reporting Person was granted 68,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 17:25 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 17,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-073113 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 18:54 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 71,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-071930 · a4.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,250 Underlying: Common Stock · 71,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 18:54 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 142,500 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001104659-19-071930 · a4.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 142,500 shares Expires 2029-12-08 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 16:08 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001562180-19-000563 · primarydocument.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-01-25 F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on January 25, 2020. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 20:34 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 3,859 | $1.30 | $5,016.70 |
DisclosureSEC source: 0001104659-19-001169 · a4.xml · nonDerivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,164 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2019. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 20:34 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-001169 · a4.xml · derivative · entry 3 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F3 · derivative.exercise_date: On January 4, 2016, the reporting person was granted an award of 25,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 20:34 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-001169 · a4.xml · nonDerivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.